Ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant {beta}-lactam resistance mechanism

Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant {beta}-lactam resistance mechanisms. [PublishAheadOfPrint]:

The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 P. aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or MDR profiles (27% to 77.8%). MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained ≤4 μg/mL for a panel of 16 PAO1 isogenic mutants, expressing multiple combinations of the most relevant β-lactam resistance mechanisms.



http://ift.tt/2aeneR0